"Fort de plus de 5 500 collaborateurs et médecins, le Groupe Jolimont fédère un réseau d’institutions actives dans le Brabant Wallon et le Hainaut. Celles-ci ont pour but d’établir entre elles diverses formes de solidarité, de partager des compétences, des valeurs humaines, des intérêts scientifiques, de renforcer leur complémentarité en étant actives dans le domaine des soins hospitaliers et ambulatoires et dans les domaines de l’accueil des enfants, des personnes âgées et de toute personne en difficulté de vie. Le Groupe Jolimont est le premier groupe de santé wallon."

During the past decade, Hopital de Jolimont conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 19 clinical trials were completed, i.e. on average, 42.2% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 9 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital de Jolimont" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 20 trials, followed by "The Lymphoma Academic Research Organisation" with 9 trials sponsored, "Cliniques universitaires Saint-Luc- Université Catholique de Louvain" with 8 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored and "Celgene" with 7 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital de Jolimont" #1 collaborator was "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Federation Francophone de Cancerologie Digestive" with 2 trials as a collaborator and "Grand Hôpital de Charleroi" with 2 trials as a collaborator. Other collaborators include 54 different institutions and companies that were collaborators in the rest 60 trials.

According to Clinical.Site data, the most researched conditions in "Hopital de Jolimont" are "Breast Cancer" (7 trials), "Multiple Myeloma" (5 trials), "Lung Cancer" (4 trials), "Acute Myeloid Leukemia" (3 trials) and "Chronic Lymphocytic Leukemia" (3 trials). Many other conditions were trialed in "Hopital de Jolimont" in a lesser frequency.

Most popular intervention types in "Hopital de Jolimont" are "Drug" (75 trials), "Procedure" (13 trials), "Radiation" (11 trials), "Other" (9 trials) and "Biological" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "radiation therapy" (8 trials), "Rituximab" (7 trials), "Lenalidomide" (5 trials) and "adjuvant therapy" (5 trials). Other intervention names were less common.

The vast majority of trials in "Hopital de Jolimont" are 87 trials for "All" genders, 8 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hopital de Jolimont". undefined are not yet recruiting, 16 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 50 completed trials in Hopital de Jolimont, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital de Jolimont, 4 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 52 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".